Trijardy XR 5 mg/1

Trijardy XR 5 mg/1 combines empagliflozin, linagliptin, and metformin for managing type 2 diabetes. This extended-release tablet supports blood sugar control and is taken orally.

Trijardy XR 5 mg/1 is designed to help manage type 2 diabetes by improving blood sugar levels. It combines three active ingredients: empagliflozin, linagliptin, and metformin. Empagliflozin works by helping the kidneys remove excess glucose from the body, while linagliptin and metformin work in different ways to lower blood sugar. This medication is typically used as part of a broader treatment plan that includes diet and exercise.

Common effects of Trijardy XR 5 mg/1 may include symptoms such as nausea, diarrhea, and headache. Some individuals might also experience urinary tract infections or low blood sugar, especially when combined with other diabetes medications. It's important to monitor for any unusual symptoms and consult a healthcare provider if they persist or worsen.

Trijardy XR 5 mg/1 should be handled with care, especially for those with kidney issues, as empagliflozin can affect kidney function. It is important to stay hydrated and avoid activities that may lead to dehydration. This medication should be stored at room temperature and kept out of reach of children. Always follow the advice of a healthcare professional regarding its use.

Trijardy XR 5 mg/1 may interact with certain medications, including other diabetes drugs, diuretics, and some antibiotics. Alcohol can also affect how this medication works and should be avoided. It is important to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.